У нас вы можете посмотреть бесплатно Infection, Immunity and the Brain: Clinical Implications for Neuropsychiatric Disease. или скачать в максимальном доступном качестве, видео которое было загружено на ютуб. Для загрузки выберите вариант из формы ниже:
Если кнопки скачивания не
загрузились
НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием видео, пожалуйста напишите в поддержку по адресу внизу
страницы.
Спасибо за использование сервиса ClipSaver.ru
Infection, Immunity and the Brain: Clinical Implications for Neuropsychiatric Disease. The key role of autoantibody biomarkers. What happens when infections & the immune system target the brain? This webinar discusses the impact infections can have on the immune system and the brain, leading to the onset of various neurologic and psychiatric symptoms. And how testing with the Autoimmune Brain Panel can help identify patients with immune-mediated neuropsychiatric conditions. LEARN MORE: https://www.moleculera.com/about-auto... Common infections (i.e., strep, influenza and mycoplasma pneumoniae) can trigger an abnormal autoimmune response, in which antibodies produced to destroy harmful pathogens (i.e., bacteria, viruses) mistakenly attack portions of the brain. This autoimmune attack disrupts how cells and receptors function and causes brain inflammation, resulting in a range of neuropsychiatric symptoms. This presentation will review the biological process behind these infection-triggered autoimmune neuropsychiatric disorders. Dr. Shimasaki will discuss how infections can impact the immune system and the brain, leading to the onset of various neurologic and psychiatric symptoms, including OCD, tics, depression, anxiety and even seizure-like movements. Dr. Shimasaki will describe several signs and symptoms that may help identify individuals with an autoimmune-induced neuropsychiatric condition. He will also review how testing with the Autoimmune Brain Panel™ can assist clinicians in determining whether symptoms may be due to an autoimmune response, rather than a primary neurologic or psychiatric disorder. The presentation will highlight several patients who, after testing positive on the Panel, were treated successfully with a complete resolution of their symptoms.